Print Page      Close Window

Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$13.53 + 1.36
Stock chart for: TOCA.O.  Currently trading at $13.53 with a 52 week high of $14.66 and a 52 week low of $7.52.
09/20/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Announces Early Completion of Enrollment in Toca 5 Pivotal Phase 3 Brain Cancer Trial

09/19/18

Read More

Tocagen to Participate in Two Investor Conferences Next Week

08/28/18

Read More

Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis

08/23/18

Read More

Recent Presentation

View All  
DateTitle
09/05/18
Download Documentation Corporate Presentation – September 2018
05/21/18
Download Documentation Toca 511 & Toca FC: Evaluation of durable response rate in the post-resection setting and association with survival in patients with recurrent high grade glioma

Upcoming Events

View All  
There are currently no events scheduled.